Official Best of San Antonio Breast Cancer Symposium®

Saturday, April 7, 2018, 8:00 AM - 1:00 PM, Andrews Academic Tower Room 1000-A


This state-of-the-art symposium is on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer, and premalignant breast disease.  This seminar is directed towards health care professionals involved in breast cancer in medical, surgical, gynecologic and radiation oncology.  

1. Discuss the significant clinical interest of abscopal response and the potential use in treating breast cancer.
2. Discuss the finding and potential innovations resulting from the I Spy trials.
3. Describe the state of the art information on hormonal therapy and optimal chemoprevention in breast cancer survivors and women at high risk.
4. Discuss the use of a breast cancer survivorship life-care plan for patients.

Physicians: $50
Other Health Professionals: $20

Registration Fees are non-refundable

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical  Education (ACCME) through the joint providership of the University of Oklahoma College of Medicine and the Oklahoma Society of Clinical Oncology, Inc.  The University of Oklahoma College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nondiscrimination Statement: 
The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices or procedures. This includes, but is not limited to: admissions, employment, financial aid and educational services. Inquiries regarding non-discrimination policies may be directed to: Bobby J. Mason, Institutional Equity Officer, (405) 325-3546, [email protected], or visit www.ou.edu/eoo.

Accommodation Statement: 
Accommodations on the basis of disability are available by contacting Kathy Musson at (405) 850-8334 or mailto:[email protected] as soon as possible.

Disclaimer Statement: 
Statements, opinions and results of studies contained in the program are those of the presenters, authors and joint provider and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

Policy on Faculty, Presenters and Joint Provider Disclosure: 
It is the policy of the University of Oklahoma, College of Medicine that the faculty, presenters and joint provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s).  

AMA PRA Category 1 Credits™ (3.75 hours), Non-Physician Attendance (3.75 hours)

Planning Committee Members:

   William C Dooley, MD, FACS    Bio
                       Past President, Oklahoma Society of Clinical Oncology, Inc.                        
                       Course Director  

     Joseph P Lynch, MD, FACS
                      President, Oklahoma Society of Clinical Oncology, Inc.

    Bilal Khalid, MD    Bio
                     Senior Fellow PGY6


Kathy A Musson
   Course Contact

Planning committee disclosures and resolutions will be available in the course syllabus.

Saturday, April 7, 2018

Acknowledgement of Commercial and In-Kind Support: 
Commercial support is financial, or in-kind, contributions given by a commercial interest, which is used to pay all or part of the costs of a CME activity.  A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.This activity received no commercial or in-kind support.